INSMED Inc

INSM Nasdaq CIK: 0001104506

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Large accelerated filer
State of Incorporation VA
Business Address 700 US HIGHWAY 202/206, BRIDGEWATER, NJ, 08807
Mailing Address 700 US HIGHWAY 202/206, BRIDGEWATER, NJ, 08807
Phone 908-977-9900
Fiscal Year End 1231
EIN 541972729

Financial Overview

FY2024

$-3.91
EPS

Recent SEC Filings

Form Type Date Filed Document
4 Insider stock transaction report February 11, 2026 View on SEC
4 Insider stock transaction report February 11, 2026 View on SEC
4 Insider stock transaction report February 6, 2026 View on SEC
4 Insider stock transaction report February 4, 2026 View on SEC
4 Insider stock transaction report February 4, 2026 View on SEC
4 Insider stock transaction report February 4, 2026 View on SEC
4 Insider stock transaction report February 4, 2026 View on SEC
4 Insider stock transaction report February 4, 2026 View on SEC
4 Insider stock transaction report January 22, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment January 21, 2026 View on SEC

Material Events

8-K Strategy Change December 17, 2025
High Impact
  • INSMED Inc. discontinued the development of brensocatib for chronic rhinosinusitis without nasal polyps (CRSsNP) due to insufficient results in its Phase 2b study.
  • The company acquired a new potential drug, INS1148, which it plans to develop for interstitial lung disease and moderate-to-severe asthma.
View Analysis

Insider Trading

STRONG SELL 8 insiders 77 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.